Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 7/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24630979 | 0.95 | SIGMAR1 (0.40) | LMNAKDM4ESIGMAR1HTR1AADRB1 | |
| SCHEMBL22864136 | 0.85 | KDM4E (0.40) | LMNAKDM4ESIGMAR1HTR1AADRB1 | |
| SCHEMBL24630993 | 0.82 | ADRB2 (0.48) | HTR1AADRB1ADRB2 | |
| SCHEMBL24630999 | 0.80 | SIGMAR1 (0.38) | KDM4ESIGMAR1HTR1AADRB1ADRB2 | |
| SCHEMBL24630930 | 0.79 | ADRB2 (0.30) | ADRB2 | |
| SCHEMBL22864140 | 0.79 | ADRB2 (0.49) | LMNAKDM4EADRB1ADRB2 | |
| SCHEMBL24630925 | 0.79 | ADRB2 (0.37) | KDM4EADRB1ADRB2 | |
| SCHEMBL24630995 | 0.78 | ADRB2 (0.31) | ADRB1ADRB2 | |
| SCHEMBL24630913 | 0.76 | ADRB2 (0.37) | KDM4EADRB1ADRB2 | |
| SCHEMBL6925470 | 0.70 | GLA (0.46) | KDM4ESIGMAR1ADRB1ADRB2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | LMNA 1389/4885KDM4E 4707/4885SIGMAR1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.